Sino Biopharmaceutical (HKG:1177) invested 142 million yuan in LaNova Medicines' Series C1 financing round, securing a 4.91% stake in the company.
The funding round, which raised 300 million yuan, will support LaNova's development of new medical treatments and innovative platforms in oncology.
The parties also established cooperation in mainland China, focusing on LaNova's LM-108, a drug undergoing clinical trials to treat various cancers.
In addition, Sino Biopharm has the option to enter into other partnerships with LaNova in the future for various potential bispecific antibodies and antibody-drug conjugates.
"Through the equity investment and strategic cooperation, the Group's pipeline layout in the field of oncology will be further enriched and optimized," Sino Biopharm said in a Wednesday statement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。